Wegovy Gets Green Light in India as First‑Line Treatment for MASH, the Liver Condition Touching One‑Third of Indians

In a move that could shift the landscape of liver‑health care in the subcontinent, the Central Drugs Standard Control Organization (CDSCO) has officially cleared the weight‑loss injection Wegovy – the brand name for semaglutide – for use in adults suffering from Metabolic‑associated Steatohepatitis, commonly known as MASH.

That’s a mouthful, I know. Basically, MASH is the more severe form of non‑alcoholic fatty liver disease (NAFLD). It’s when excess fat builds up in the liver, inflammation kicks in and, over time, the organ can scar itself (cirrhosis). The scary part? Studies suggest that about one in three Indians are living with some stage of fatty‑liver disease, and a sizable chunk of them are inching towards MASH.

So why Wegovy? The drug belongs to the GLP‑1 (glucagon‑like peptide‑1) class that was originally designed to help people with type‑2 diabetes lose weight. Clinical trials abroad have shown that semaglutide not only trims the waistline but also reduces liver fat and inflammation – the two big villains in MASH. The Indian data, though still emerging, appear to echo those findings.

According to the approval notice, Wegovy will be prescribed at a dose of 2.4 mg once a week, the same regimen used for obesity management. Doctors will, of course, have to evaluate each patient’s overall health, screen for diabetes, and monitor liver function tests regularly. The drug isn’t a magic bullet, but it adds a valuable arrow to the quiver of lifestyle changes, diet, and exercise that remain the cornerstone of treatment.

For patients, the news is both hopeful and a little daunting. Wegovy is not cheap – the cost can run into several thousand rupees per month – and insurance coverage for obesity drugs is still patchy in India. Still, the approval signals that the government recognises MASH as a serious public‑health issue, not just a “fatty liver” that can be ignored.

Experts say the real win will be early detection. If doctors start screening high‑risk groups (obese, diabetic, or those with a family history of liver disease) and intervene with drugs like Wegovy, the trajectory towards cirrhosis and liver cancer could be slowed, perhaps even reversed.

In the meantime, the FDA‑like regulator has reminded clinicians that the drug’s safety profile remains consistent with global data – the most common side effects being nausea, vomiting and mild gastrointestinal discomfort. As with any medication, the benefits must outweigh the risks, and shared decision‑making with patients is essential.

Overall, the clearance marks a pivotal step for India’s fight against a silent epidemic that affects a staggering one‑third of its people. Whether Wegovy becomes a household name in liver clinics will depend on pricing, accessibility, and how quickly the medical community embraces this new therapeutic avenue.